Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Feature
  • Published:

The rise of venture capital and biotechnology in the US and Europe

Nature Biotechnology volume 23, pages 672–676 (2005)Cite this article

Biotechnology-based businesses have historically looked to venture capitalists for funding. Our recent survey shows that, unlike the public marketplace, where investors' appetite for biotechnology has waxed and waned the last few years, venture capitalists are staying the course.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Biotechnology investment area by VC funds in Europe and the United States.
Figure 2: Top ten states for biotechnology VC.
Figure 3: European biotechnology VC sites (number of sites indicated for each country).
Figure 4: Percentage of VC funds that invest in each financing stage.

References

  1. Ernst & Young. Refocus: Ernst & Young's European Biotechnology Report (Ernst and Young, London, 2004).

  2. Burrill & Company. Biotech ends on a high note. http://www.burrillandco.com/burrill/pr_1105471928. Press release, Jan. 5, 2005.

  3. European venture-capital investment climbs in first quarter of 2005. Business Wire, May 16 (2005). http://uk.biz.yahoo.com/050515/183/fiv0m.html.

  4. Burrill, G.S. Biotech 2004 Life Sciences: Back on Track, 18th Annual Report on the Industry (Burrill & Company LCC, (San Francisco, CA, USA, 2004).

    Google Scholar 

  5. Schuehsler, H. Life science venture capital: a case for Europe. Venture Capital Journal 44, 60–62, 2004.

    Google Scholar 

  6. Collins, S.W. The Race to Commercialize Biotechnology: Molecules, Markets and the State in the United States and Japan (RoutledgeCurzon, London, 2004).

    Google Scholar 

  7. PricewaterhouseCoopers/Thomson,Venture Economics and National Venture Capital Association MoneyTree Survey. Full-year & Q4 2004 results. US Report, January 3, 2005. http://www.pwcmoneytree.com/exhibits/04Q4MoneyTreeReport.pdf.

  8. PricewaterhouseCoopers/Thompson, Venture Economics and National Venture Capital Association MoneyTree Survey. Venture capital investing settles back to $4.6 billion in 2005. MoneyTree Survey. http://www.pwcmoneytree.com/exhibits/05Q1SurveyHighlights.pdf.

  9. Howell, M., Trull, M. & Dibner, M. The rise of European venture capital for biotechnology. Nat. Biotechnol. 21, 1287–1291 (2003).

    Article  CAS  Google Scholar 

  10. BioAbility, European Biotechnology Venture Capital Database (Thomson, Bioworld, Atlanta, GA, USA, 2005).

  11. BioAbility, US/Canadian Biotechnology Venture Capital Database (Thomson BioWorld Atlanta, GA, USA, 2005).

  12. European Private Equity & Venture Capital Association. Benchmark Paper: Benchmarking European Tax and Legal Environments. (Brussels, Belgium May 2004). http://www.evca.com/images/attachments/tmpl_9_art_90_att_587.pdf.

  13. Flanigan, J. Foreign funding blooms for tech in US. Los Angeles Times, April 4 2004, p. C1.

  14. Ernst & Young, SWX Swiss Exchange, the State Secretariat for Economic Affairs, the innovation promotion agency KTI/CTI, and Swiss Biotech. Swiss Biotech Report. (March 11, 2004). (http://www2.eycom.ch/publications/items/biotech_swissreport/en.pdf).

Download references

Author information

Authors and Affiliations

  1. Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, 27599, North Carolina, USA

    Douglas P Lee

  2. BioAbility, PO Box 14569, Research Triangle Park, 27709-4569, North Carolina, USA

    Mark D Dibner

Authors
  1. Douglas P Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark D Dibner
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, D., Dibner, M. The rise of venture capital and biotechnology in the US and Europe. Nat Biotechnol 23, 672–676 (2005). https://doi.org/10.1038/nbt0605-672

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt0605-672

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing